Papers - Nakajima, Shinichiro

Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans.

Le Foll B, Payer D, Di Ciano P, Guranda M, Nakajima S, Tong J, Mansouri E, Wilson AA, Houle S, Meyer JH, Graff-Guerrero A, Boileau I.

Neuropsychopharmacology.  2016

The effect of striatal dopamine depletion on striatal and cortical glutamate: A mini-review.

Caravaggio F, Nakajima S, Plitman E, Gerretsen P, Chung JK, Iwata Y, Graff-Guerrero A.

Prog Neuropsychopharmacol Biol Psychiatry.  2016

Relapse of ileus in patients with psychiatric disorders: A 2-year chart review.

Kitahata R, Nakajima S, Suzuki T, Plitman E, Mimura M, Uchida H.

Gen Hosp Psychiatry.  2016

Predicting Plasma Olanzapine Concentration Following a Change in Dosage: A Population Pharmacokinetic Study.

48. Tsuboi T, Bies R, Suzuki T, Takeuchi H, Nakajima S, Graff-Guerrero A, Mamo D, Caravaggio F, Plitman E, Mimura M, Pollock B, Uchida H.

Pharmacopsychiatry.  2016

Threshold of Dopamine D2/3 Receptor Occupancy for Hyperprolactinemia in Older Patients with Schizophrenia.

52. Iwata Y, Nakajima S, Caravaggio F, Uchida H, Suzuki T, Plitman E, Mar W, Pollock B, Mulsant BH, Rajji TK, Mamo D, Graff-Guerrero A.

Journal of Clinical Psychiatry  2016

Dopamine D2/3 Receptor Occupancy Following Dose Reduction Is Predictable With Minimal Plasma Antipsychotic Concentrations: An Open-Label Clinical Trial.

Nakajima S, Uchida H, Bies RR, Caravaggio F, Suzuki T, Plitman E, Mar W, Gerretsen P, Pollock BG, Mulsant BH, Mamo DC, Graff-Guerrero A.

Schizophr Bull.  2016

Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study.

Nagata T, Nakajima S, Shinagawa S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K.

Int J Geriatr Psychiatry.  2016

Cognition and Dopamine D2 Receptor Availability in the Striatum in Older Patients with Schizophrenia.

Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC, Graff-Guerrero A.

Am J Geriatr Psychiatry.  2016

Evaluation of Antipsychotic Dose Reduction in Late-Life Schizophrenia: A Prospective Dopamine D2/3 Receptor Occupancy Study.

Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, Uchida H, Gerretsen P, Mar W, Pollock BG, Mamo DC.

JAMA Psychiatry.  2015

Whether to increase or maintain dosage of mirtazapine in early nonimprovers with depression.

Ueno F, Nakajima S, Suzuki T, Abe T, Sato Y, Mimura M, Uchida H.

J Clin Psychiatry.  2015

Non-pharmacological management for patients with frontotemporal dementia: a systematic review.

Shinagawa S, Nakajima S, Plitman E, Graff-Guerrero A, Mimura M, Nakayama K, Miller BL.

J Alzheimers Dis.  2015

Comparative efficacy between clozapine and other atypical antipsychotics on depressive symptoms in patients with schizophrenia: analysis of the CATIE phase 2E data.

Nakajima S, Takeuchi H, Fervaha G, Plitman E, Chung JK, Caravaggio F, Iwata Y, Mihashi Y, Gerretsen P, Remington G, Mulsant B, Graff-Guerrero A.

Schizophr Res.  2015

Lifetime History of Depression Predicts Increased Amyloid-β Accumulation in Patients with Mild Cognitive Impairment.

Chung JK, Plitman E, Nakajima S, Chow TW, Chakravarty MM, Caravaggio F, Gerretsen P, Brown EE, Iwata Y, Mulsant BH, Graff-Guerrero A; Alzheimer's Disease Neuroimaging Initiative.

J Alzheimers Dis.  2015

Neuroimaging findings in treatment-resistant schizophrenia: A systematic review: Lack of neuroimaging correlates of treatment-resistant schizophrenia.

Nakajima S, Takeuchi H2, Plitman E, Fervaha G, Gerretsen P, Caravaggio F, Chung JK, Iwata Y, Remington G, Graff-Guerrero A.

Schizophr Res.  2015

Reduced insulin sensitivity is related to less endogenous dopamine at D2/3 receptors in the ventral striatum of healthy nonobese humans.

Caravaggio F, Borlido C, Hahn M, Feng Z, Fervaha G, Gerretsen P, Nakajima S, Plitman E, Chung JK, Iwata Y, Wilson A, Remington G, Graff-Guerrero A.

Int J Neuropsychopharmacol  2015

Dopamine D₂/₃ receptor availability in the striatum of antipsychotic-free older patients with schizophrenia-A [¹¹C]-raclopride PET study.

Nakajima S, Caravaggio F, Mamo DC, Mulsant BH, Chung JK, Plitman E, Iwata Y, Gerretsen P, Uchida H, Suzuki T, Mar W, Wilson AA, Houle S, Graff-Guerrero A.

Schizophr Res.  2015

Cortical beta-amyloid deposition and life-time depressive symptoms in Alzheimer’s disease and mild cognitive impairment.

32. Chung J, Plitman E, Nakajima S, Chow T, Chakravarty M, Caravaggio F, Gerretsen P, Brown E, Iwata Y, Graff-Guerrero A, for the Alzheimer’s Disease Neuroimaging Initiative.

J Alzheimers Dis. (in press)  2015

Fear conditioning induced by interpersonal conflicts in healthy individuals.

Tada M, Uchida H, Maeda T, Konishi M, Umeda S, Terasawa Y, Nakajima S, Mimura M, Miyazaki T, Takahashi T.

PLoS One.  2015

Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO.

Boileau I, Nakajima S, Payer D.

Eur Neuropsychopharmacol.  2015

Lack of Decrease in Dopamine D3 receptor Availability - [11C]-(+)-PHNO and [11C]-Raclopride Positron Emission Tomography Study.

Nakajima S, Caravaggio F, Gerretsen P, Plitman E, Chung J, Iwata Y, Wilson A, Houle S, Menon M, Mamo D, Graff-Guerrero A.

Journal of Cerebral Blood Flow & Metabolism  2015